Author:
Al-Monajjed R.,Arsov C.,Albers P
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725–732
2. Schröder FH, Hugosson J, Carlsson S et al (2012) Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European randomized study of screening for prostate cancer (ERSPC). Eur Urol 62:745–752
3. Schröder FH, Hugosson J, Roobol MJ et al (2014) Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035
4. Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R (2016) Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol 2:890–898
5. Gemeinsamer Bundesausschuss (2020) Prostatakrebs: G‑BA hält an PSA-Wert-Bestimmung bei der Behandlung fest – kein Einsatz in der Früherkennung. ww.g-ba.de. Zugegriffen: 02.2021 (Nr. 68 / 2020)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献